AVB 114
Alternative Names: Autologous mesenchymal stromal cell coated fistula plug - Avobis Bio; AVB-114; MSC-AFPLatest Information Update: 10 Mar 2025
At a glance
- Originator Mayo Clinic; W. L. Gore & Associates
- Developer Avobis Bio; Mayo Clinic
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rectal fistula
Most Recent Events
- 27 Feb 2025 AVB 114 receives Fast Track designation for Rectal fistula [Parenteral] (Treatment-experienced) in USA
- 27 Feb 2025 AVB 114 receives IND clearance from the US FDA for Crohn's perianal fistulas in USA, prior to February 2025
- 27 Feb 2025 Avobis Bio completes enrolment in a phase II trial in Rectal fistula (Treatment-experienced) in USA (Parenteral), prior to February 2025 (NCT04847739)